Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea.
Biotechnol Adv. 2014 Nov 1;32(6):1123-32. doi: 10.1016/j.biotechadv.2014.03.009. Epub 2014 Apr 1.
Carcinogenesis is a complex and multistep process that involves the accumulation of successive transformational events driven by genetic mutations and epigenetic alterations that affect major cellular processes and pathways such as proliferation, differentiation, invasion and survival. Massive deregulation of all components of the epigenetic machinery is a hallmark of cancer. These alterations affect normal gene regulation and impede normal cellular processes including cell cycle, DNA repair, cell growth, differentiation and apoptosis. Since epigenetic alterations appear early in cancer development and represent potentially initiating events during carcinogenesis, they are considered as promising targets for anti-cancer interventions by chemopreventive and chemotherapeutic strategies using epigenetically active agents. In this field, plant-derived compounds have shown promise. Here, we will give an overview of plant-derived compounds displaying anticancer properties that interfere with the epigenetic machinery.
致癌作用是一个复杂的多步骤过程,涉及由遗传突变和表观遗传改变驱动的连续转化事件的积累,这些改变影响主要的细胞过程和途径,如增殖、分化、侵袭和存活。表观遗传机制的所有成分的大规模失调是癌症的一个标志。这些改变会影响正常的基因调控,并阻碍包括细胞周期、DNA 修复、细胞生长、分化和凋亡在内的正常细胞过程。由于表观遗传改变在癌症发展的早期出现,并且在致癌作用过程中代表潜在的起始事件,因此它们被认为是使用具有表观遗传活性的药物进行化学预防和化学治疗策略的抗癌干预的有希望的靶点。在这一领域,植物来源的化合物显示出了希望。在这里,我们将概述具有干扰表观遗传机制的抗癌特性的植物来源化合物。